目的 探討速效救心丸聯(lián)合阿羅洛爾治療心絞痛的臨床療效。方法 選取2018年12月—2021年12月攀枝花市中西醫(yī)結(jié)合醫(yī)院收治的136例心絞痛患者，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各68例。對(duì)照組口服鹽酸阿羅洛爾片，10mg/次，2次/d。治療組在對(duì)照組基礎(chǔ)上含服速效救心丸，5粒/次，3次/d。兩組均連續(xù)治療8周。觀察兩組的臨床療效，比較兩組治療前后心絞痛發(fā)作情況（次數(shù)和持續(xù)時(shí)間）、心絞痛視覺模擬評(píng)分（VAS）、血瘀證評(píng)分、西雅圖心絞痛量表（SAQ）評(píng)分，以及血清內(nèi)皮素-1（ET-1）、一氧化氮（NO）、超氧化物歧化酶（SOD）、單核細(xì)胞趨化蛋白-1（MCP-1）、基質(zhì)金屬蛋白酶-9（MMP-9）水平。結(jié)果 治療后，治療組總有效率是92.6%，顯著高于對(duì)照組的80.9%（P＜0.05）。兩組心絞痛發(fā)作次數(shù)均較治療前顯著減少，持續(xù)時(shí)間則均顯著縮短（P＜0.05）；且均以治療組改善更顯著（P＜0.05）。兩組治療后心絞痛VAS評(píng)分和血瘀證評(píng)分均顯著降低，SAQ評(píng)分則均顯著增加（P＜0.05）；且治療組以上評(píng)分改善更顯著（P＜0.05）。治療后兩組血清ET-1、MCP-1、MMP-9水平均顯著下降，血清NO、SOD水平均顯著上升（P＜0.05）；且均以治療組改善更顯著（P＜0.05）。結(jié)論 速效救心丸聯(lián)合阿羅洛爾治療心絞痛的總體療效確切，能安全有效地控制患者心絞痛發(fā)作，減輕機(jī)體氧化應(yīng)激和炎性損傷，保護(hù)血管內(nèi)皮功能，改善患者生活質(zhì)量。

Objective To investigate the clinical efficacy of Suxiao Jiuxin Pills combined with arotinolol in treatment of angina pectoris. Methods A total of 136 patients with angina pectoris admitted to Panzhihua Integrated Traditional Chinese and Western Medicine Hospital from December 2018 to December 2021 were selected and divided into control group and treatment group according to the random number table method, with 68 cases in each group. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 10 mg/time, twice daily. Patients in the treatment group were po administered with Suxiao Jiuxin Pills on the basis of the control group, 5 grains/time, three times daily. Both groups were treated for 8 weeks. The clinical efficacy of the two groups was observed, and the angina attacks (times and duration), visual analogue scale (VAS) score, blood stasis syndrome score, Seattle Angina Scale (SAQ) score, serum endothelin-1 (ET-1), nitric oxide (NO), superoxide dismutase (SOD), monocyte chemotactic protein-1 (MCP-1), and matrix metalloproteinase-9 (MMP-9) levels before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 92.6%, which was significantly higher than 80.9% of the control group (P<0.05). The frequency and duration of angina attacks in the two groups were significantly reduced compared with those before treatment (P<0.05). The improvement was more significant in the treatment group (P<0.05). After treatment, VAS score and blood stasis syndrome score of angina pectoris were significantly decreased, and SAQ score was significantly increased in both groups (P<0.05). The above scores of the treatment group were improved more significantly (P<0.05). After treatment, the serum levels of ET-1, MCP-1, and MMP-9 in the two groups were significantly decreased, and the serum levels of NO and SOD were significantly increased (P<0.05). The improvement was more significant in the treatment group (P<0.05). Conclusion Suxiao Jiuxin Pills combined with arotinolol has a definite overall curative effect in treatment of angina pectoris, and can safely and effectively control the attack of angina pectoris, reduce oxidative stress and inflammatory injury, protect vascular endothelial function, which can improve the quality of life of patients.

R972